NEUROAID EARLY POST STROKE: PRELIMINARY RESULTS OF A MULTICENTRE STUDY

Józef Opara, Jarosław Szczygieł, Anna Tomasova, Dagmar Ballayova

1. "Repty" Rehab Centre in Tarnowskie Góry, Poland

2. Všeobecná nemocnica s poliklinikou, Levoča, Slovakia

3. Poliklinika CORRIB, Neurologická ambulancia, Poprad, Slovakia

AIM: The aim of this study was to assess the safety and potential efficacy of NuroAiD II in the early stage post stroke, not later than six months after stroke onset in the Eastern European population.

MATERIAL AND METHODS: The NeuroAiD Safe Treatment (NeST) Registry (clinicaltrials.gov NCT02536079) is a product registry provides information on the use and safety of NeuroAiD in clinical practice. We analysed anonymized information of ischemic injury from Slovakia and Poland. Patients consented are prospectively entered using online forms for baseline and subsequent visits. Data collected includes demographics, diagnosis, medical history, modified Rankin Score (mRS), Glasgow Coma Scale (GCS), National Institute of Health Stroke Scale (NIHSS), compliance, and side effects. Treatment:

NURAID is a composition of natural herbal extracts

Narayanaswamy Venketasubramanian et al.

The NeuroAiD Safe Treatment (NeST) Registry: a protocol. BMJ Open 2015;5:e009866.


Dosage: 3 times two capsules daily, 3 month

RESULTS: Twenty-nine consecutive patients from Slovakia and Poland were included with mean age of 62.29±12.51 years, with 12 (41.38%) women. Median NIHSS for the patients was 7 (1-23) at baseline, 6 (0-17) at M (month) 1, 4 (0-16) at M2 and 3 (0-15) at M3 (Figure 1). mRS was improving over time (Figure 2). There were no side effects reported. One patient was lost of follow-up.















Median NIHSS was 7.50 (1-23) at baseline, 6 (0-17) at V2 (month one), 4 (0-16) at V3 (month two) and 3 (0-15) at V4 (month three)





mRS was improving over time No side effects

CONCLUSIONS:

NuroAiD II was safe in ischemic stroke in two Eastern European countries who improved on functional and neurological measures.

Reference:

Narayanaswamy Venketasubramanian et al. The NeuroAiD Safe Treatment (NeST) Registry: a protocol. BMJ Open 2015;5:e009866. doi:10.1136/bmjopen-2015-009866.